Withaferin A (WFA)

Catalog No.S8587 Batch:S858702

Print

Technical Data

Formula

C28H38O6
Molecular Weight 470.60 CAS No. 5119-48-2
Solubility (25°C)* In vitro DMSO 97 mg/mL (206.11 mM)
Ethanol 4 mg/mL (8.49 mM)
Water Insoluble
In vivo (Add solvents to the product individually and in order)
Clear solution
5%DMSO 40%PEG300 5%Tween80 50%ddH2O
4.85mg/ml Taking the 1 mL working solution as an example, add 50 μL of 97 mg/ml clarified DMSO stock solution to 400 μL of PEG300, mix evenly to clarify it; add 50 μL of Tween80 to the above system, mix evenly to clarify; then continue to add 500 μL of ddH2O to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results. 
Clear solution
5% DMSO 95% Corn oil
1.21mg/ml Taking the 1 mL working solution as an example, add 50 μL of 24.2 mg/ml clear DMSO stock solution to 950 μL of corn oil and mix evenly. The mixed solution should be used immediately for optimal results. 
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
* Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

Biological Activity

Description Withaferin A (WFA) potently inhibits NF-κB activation by preventing the tumor necrosis factor-induced activation of IκB kinase β via a thioalkylation-sensitive redox mechanism. Withaferin A binds to the intermediate filament (IF) protein, vimentin with antitumor and antiangiogenesis activity. Withaferin A is a steroidal lactone isolated from Withania somnifera.
Targets
NF-κB [1] vimentin [2]
In vitro

Withaferin A potently inhibits NFκB activation by preventing the tumor necrosis factor-induced activation of IκB kinase β via a thioalkylation-sensitive redox mechanism.[1] Withaferin A binds to the intermediate filament (IF) protein, vimentin, by covalently modifying its cysteine residue, which is present in the highly conserved α-helical coiled coil 2B domain. Withaferin A induces vimentin filaments to aggregate in vitro.[2]
In vivo

Withagerin A clearly displays anti-inflammatory characteristics in an acute inflammatory mouse model.[1] Withagerin A-induced inhibition of capillary growth in a mouse model of corneal neovascularization is compromised in vimentin-deficient mice.[2]

Protocol (from reference)

Cell Assay:

[2]
  • Cell lines

    HUVECs, BAECs,MCF-7 breast cancer cell line, MFT-16 cells

  • Concentrations

    5 μM, 10 μM

  • Incubation Time

    1 h, 2 h, 24 h

  • Method

    To assess the apoptosis activity of WFA and 12-D WS, embryonic fibroblast vimentindeficient cell lines (Vim−/−; MFT-16) and wild-type (Vim+/+; MFT-6) cells are treated with 5 μM WFA, 5 μM 12-D WS, or an equivalent amount of vehicle (DMSO) for 24 hr in 37℃-5% CO2 conditions in complete medium. Apoptotic cells are measured with the Vybrant Apoptosis Assay Kit according to the manufacturer's instructions.
Animal Study:

[1]
  • Animal Models

    8-week-old C57BL/6J mice

  • Dosages

    0.5 mg/mouse

  • Administration

    IP

Selleck's Withaferin A (WFA) has been cited by 10 publications

A Gene Co-Expression Network-Based Drug Repositioning Approach Identifies Candidates for Treatment of Hepatocellular Carcinoma [ Cancers (Basel), 2022, 14(6)1573] PubMed: 35326724
A redox-sensitive iron-sulfur cluster in murine FAM72A controls its ability to degrade the nuclear form of uracil-DNA glycosylase [ DNA Repair (Amst), 2022, 118:103381] PubMed: 35908367
HIV-1 Proteins gp120 and Tat Promote Epithelial-Mesenchymal Transition and Invasiveness of HPV-Positive and HPV-Negative Neoplastic Genital and Oral Epithelial Cells [ Microbiol Spectr, 2022, 10(6):e0362222.] PubMed: 36314970
Withaferin A Triggers Apoptosis and DNA Damage in Bladder Cancer J82 Cells through Oxidative Stress [ Antioxidants (Basel), 2021, 10(7)1063] PubMed: 34209212
The Activin/FLRG pathway associates with poor COVID-19 outcomes in hospitalized patients [ Mol Cell Biol, 2021, MCB0046721] PubMed: 34723652
Activin A correlates with the worst outcomes in COVID-19 patients, and can be induced by cytokines via the IKK/NF-kappa B pathway [ bioRxiv, 2021, 10.1101/2021.02.04.429815] PubMed: N/A
Low Concentration of Withaferin a Inhibits Oxidative Stress-Mediated Migration and Invasion in Oral Cancer Cells [ Biomolecules, 2020, 10(5)E777] PubMed: 32429564
Withaferin A Induces Oxidative Stress-Mediated Apoptosis and DNA Damage in Oral Cancer Cells [ Front Physiol, 2017, 8:634] PubMed: 28936177
Synergistic inhibition of glioma cell proliferation by Withaferin A and tumor treating fields [ J Neurooncol, 2017, 134(2):259-268] PubMed: 28681243
AshwaMAX and Withaferin A inhibits gliomas in cellular and murine orthotopic models [ J Neurooncol, 2016, 126(2):253-64] PubMed: 26650066

RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.

SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.